September 14, 2020
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
SEPTEMBER 8, 2020
Biophytis recently attended the Digital ChinaBio conference taking place August 25-27, and will also attend the following conferences: The HC Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020 (Virtual Conference) The HTID (Health Tech Innovation Days): October 5th & 6th, Paris Bio Europe Fall : October 26-29th (Virtual Conference)
SEPTEMBER 1ST, 2020
Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
August 28, 2020
Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia. Read the Press Release
AUGUST 4, 2020
Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release
JULY 27, 2020
Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
JULY 3, 2020
Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release
JULY 1st, 2020
Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
JULY 1st, 2020
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
June 23, 2020
Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure. Read the Press Release